

Provider Update

Precertification Required for Hemophilia Drugs

Amerigroup Community Care precertification requirements will change for certain hemophilia drugs. The 2015 Medicare Advantage list hemophilia drugs requiring precertification. **As of July 1, 2015 providers must call for prior authorization of these drugs:**

- C9136 Factor VIII, fc fusion protein, (recombinant)
- J7178 Human fibrinogen concentrate
- J7180 Factor XIII (antihemophilic factor, human)
- J7181 Factor XIII A-subunit, (recombinant), [Tretten]
- J7182 Factor VIII, (antihemophilic factor, recombinant), [Novoeight]
- J7183 Von Willebrand factor complex (human), Wilate
- J7185 Factor VIII (antihemophilic factor, recombinant) [Xyntha]
- J7186 Antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII IU [Alphanate]
- J7187 Von Willebrand factor complex [Humate-P]
- J7189 Factor VIIa (antihemophilic factor, recombinant)
- J7190 Factor VIII antihemophilic factor, human, [Hemofil M, Doate DVI, Monoclalte-P]
- J7191 Factor VIII, antihemophilic factor [porcine]
- J7192 Factor VIII (antihemophilic factor, recombinant), [Advate, Helixate-FS, Kogenate-FS, Recombinate]
- J7193 Factor IX (antihemophilic factor, purified, non-recombinant) p [AlphaNine SD, Mononine]
- J7194 Factor IX complex, [Bebulin VH, Profilnine SD]
- J7195 Factor IX (antihemophilic factor, recombinant) ,[Benefix]
- J7198 Anti-inhibitor
- J7199 Hemophilia clotting factor, [Eloctate]
- J7200 Factor IX, (antihemophilic factor, recombinant), [Rixubis]
- J7201 Factor IX, Fc fusion protein (recombinant),

52703WPSNABC 03/25/15

Amerivantage is an HMO plan with a Medicare contract and a contract with the New Jersey Medicaid program. Enrollment in Amerivantage depends on contract renewal.

